20 Elite Compounders Quietly Trading Below Fair Value (March 2026)

A ranked capital allocation framework of high-quality businesses trading below 12-month fair value.

The market doesn’t announce when it improves your odds.

It doesn’t ring a bell.
It doesn’t send a notification.
It doesn’t turn the heatmap green first.

It simply compresses valuations… quietly.

And if fundamentals remain intact while multiples fall, expected returns rise.

That is what is happening right now.

This month, instead of screening for “high yield,” I focused on something more important:

Elite businesses trading below 12-month fair value.

Not meme stocks.
Not broken balance sheets.
Not turnaround speculation.

High-quality compounders with durable free cash flow, strong ROIC, and resilient earnings power.

And many are trading 20–60% below where I estimate fair value over the next 12 months.

---

What’s Changed In March

Last month’s list focused primarily on undervalued dividend stocks.

This month is different.

March’s spreadsheet ranks companies by:

• 12-Month Expected Return (fair value gap + yield)
• Bear Case Return (conservative valuation scenario)
• Allocation Rank (upside + ROIC + balance sheet strength)
• Conviction Tier
• Personal ownership disclosure

Instead of just asking:

“Is this cheap?”

We ask:

“What is the expected return over the next 12 months - and is the business high quality enough to justify it?”

That distinction matters.

---

What Stands Out This Month

1️⃣ Valuation Compression in Quality

Several elite compounders are trading well below their long-term valuation norms:

Microsoft
Mastercard
Accenture
Intuit
S&P Global
ADP
Novo Nordisk

These are not distressed businesses.

They are businesses the market is temporarily repricing.

That creates opportunity.

---

2️⃣ Healthcare Mispricing

Healthcare continues to show asymmetric setups.

Novo Nordisk
UnitedHealth
Abbott
Zoetis
Elevance

are trading below historical valuation bands despite strong free cash flow and durable demand.

---

3️⃣ Financials & Asset Managers Reset

Several financials and alternative asset managers have seen valuation compression despite long-term structural growth drivers.

The spreadsheet quantifies whether that compression translates into compelling 12-month return potential - not just a low P/E ratio.

---

How This Spreadsheet Is Designed To Be Used

The March file includes:

• A ranked Capital Allocation table
• 12-Month Expected Return
• 12-Month Bear Case Return
• Allocation ranking combining upside, ROIC, and leverage
• Conviction tiers
• Personal ownership disclosure

You can approach it three ways:

Income Focus → Dividend Yield
Value Focus → % From Expected Price
Quality Focus → ROIC + Net Debt

This is a capital allocation framework.

Not a shopping list.

---

Risk Context

Not every name is recession-proof.

Some have experienced significant drawdowns during past downturns.

That’s why I include:

• Bear case return assumptions
• Balance sheet metrics
• Quality filters

Opportunity exists when valuations compress - not when risk disappears.

---

Why This Matters Now

When markets are euphoric, expected returns fall.

When markets compress quality, expected returns rise.

The best setups rarely look exciting in the moment.

They look boring.
They look uncertain.
They look temporarily out of favour.

But the math improves quietly before sentiment does.

That’s what this spreadsheet is designed to capture.

---

What Paid Members Get

Premium members receive:

• Two fully updated stock spreadsheets per month
• Ranked capital allocation tables
• 12-month expected return modelling
• Ongoing valuation updates
• Exclusive breakdowns and thesis updates

At £200/year, this is designed for investors who want structure, discipline, and a repeatable framework.

Not noise.

---

March Spreadsheet

March Undervalued Compounders – Dividend Talks
Download available below for paid members.